203 related articles for article (PubMed ID: 27941393)
1. Use of rosuvastatin in HIV-associated chronic obstructive pulmonary disease.
Morris A; Fitzpatrick M; Bertolet M; Qin S; Kingsley L; Leo N; Kessinger C; Michael H; Mcmahon D; Weinman R; Stone S; Leader JK; Kleerup E; Huang L; Wisniewski SR
AIDS; 2017 Feb; 31(4):539-544. PubMed ID: 27941393
[TBL] [Abstract][Full Text] [Related]
2. Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection.
Longenecker CT; Sattar A; Gilkeson R; McComsey GA
AIDS; 2016 Sep; 30(14):2195-203. PubMed ID: 27203715
[TBL] [Abstract][Full Text] [Related]
3. A prospective, randomized study: Evaluation of the effect of rosuvastatin in patients with chronic obstructive pulmonary disease and pulmonary hypertension.
Chogtu B; Kuriachan S; Magazine R; Shetty KR; Kamath A; George MM; Tripathy A; Kumar DM
Indian J Pharmacol; 2016; 48(5):503-508. PubMed ID: 27721534
[TBL] [Abstract][Full Text] [Related]
4. Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial.
Neukamm A; Høiseth AD; Einvik G; Lehmann S; Hagve TA; Søyseth V; Omland T
J Intern Med; 2015 Jul; 278(1):59-67. PubMed ID: 25495178
[TBL] [Abstract][Full Text] [Related]
5. Statin therapy decreases N-terminal pro-B-type natriuretic peptide in HIV: randomized placebo-controlled trial.
Dirajlal-Fargo S; Kinley B; Jiang Y; Longenecker CT; Hileman CO; Debanne S; McComsey GA
AIDS; 2015 Jan; 29(3):313-21. PubMed ID: 25686680
[TBL] [Abstract][Full Text] [Related]
6. Effects of 96 Weeks of Rosuvastatin on Bone, Muscle, and Fat in HIV-Infected Adults on Effective Antiretroviral Therapy.
Erlandson KM; Jiang Y; Debanne SM; McComsey GA
AIDS Res Hum Retroviruses; 2016 Apr; 32(4):311-6. PubMed ID: 26477698
[TBL] [Abstract][Full Text] [Related]
7. Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients.
Saeedi R; Johns K; Frohlich J; Bennett MT; Bondy G
Lipids Health Dis; 2015 Jun; 14():57. PubMed ID: 26087958
[TBL] [Abstract][Full Text] [Related]
8. Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV.
Hileman CO; Turner R; Funderburg NT; Semba RD; McComsey GA
AIDS; 2016 Jan; 30(1):65-73. PubMed ID: 26731754
[TBL] [Abstract][Full Text] [Related]
9. Short Communication: The Effect of Rosuvastatin on Vascular Disease Differs by Smoking Status in Treated HIV Infection.
Hileman CO; McComsey GA
AIDS Res Hum Retroviruses; 2018 Mar; 34(3):282-285. PubMed ID: 28974102
[TBL] [Abstract][Full Text] [Related]
10. Prognostic effects of rosuvastatin in patients with co-existing chronic obstructive pulmonary disease and chronic heart failure: A sub-analysis of GISSI-HF trial.
Rossi A; Inciardi RM; Rossi A; Temporelli PL; Lucci D; Gonzini L; Marchioli R; Nicolosi GL; Tavazzi L;
Pulm Pharmacol Ther; 2017 Jun; 44():16-23. PubMed ID: 28263812
[TBL] [Abstract][Full Text] [Related]
11. Baseline Vitamin D Deficiency Decreases the Effectiveness of Statins in HIV-Infected Adults on Antiretroviral Therapy.
Hileman CO; Tangpricha V; Sattar A; McComsey GA
J Acquir Immune Defic Syndr; 2017 Apr; 74(5):539-547. PubMed ID: 28045766
[TBL] [Abstract][Full Text] [Related]
12. Rosuvastatin Worsens Insulin Resistance in HIV-Infected Adults on Antiretroviral Therapy.
Erlandson KM; Jiang Y; Debanne SM; McComsey GA
Clin Infect Dis; 2015 Nov; 61(10):1566-72. PubMed ID: 26157049
[TBL] [Abstract][Full Text] [Related]
13. [Single-breath and rebreathing methods for measurement of pulmonary diffusing function: a comparative study].
Liu QX; Zheng JP; Xie YQ; Guan WJ; Jiang CY; An JY; Yu XX; Liu WT; Gao Y
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Jul; 36(7):510-5. PubMed ID: 24262087
[TBL] [Abstract][Full Text] [Related]
14. Factors Associated With Progression of Lung Function Abnormalities in HIV-Infected Individuals.
Li Y; Nouraie SM; Kessinger C; Weinman R; Huang L; Greenblatt RM; Kleerup E; Kingsley L; McMahon D; Fitzpatrick M; Morris A
J Acquir Immune Defic Syndr; 2018 Dec; 79(4):501-509. PubMed ID: 30142142
[TBL] [Abstract][Full Text] [Related]
15. Rosuvastatin vs. protease inhibitor switching for hypercholesterolaemia: a randomized trial.
Lee FJ; Monteiro P; Baker D; Bloch M; Roth N; Finlayson R; Moore R; Hoy J; Martinez E; Carr A
HIV Med; 2016 Sep; 17(8):605-14. PubMed ID: 26987376
[TBL] [Abstract][Full Text] [Related]
16. The effect of comorbidities on COPD assessment: a pilot study.
Weinreich UM; Thomsen LP; Bielaska B; Jensen VH; Vuust M; Rees SE
Int J Chron Obstruct Pulmon Dis; 2015; 10():429-38. PubMed ID: 25750525
[TBL] [Abstract][Full Text] [Related]
17. Salmeterol improves fluid clearance from alveolar-capillary membrane in COPD patients: a pilot study.
Di Marco F; Guazzi M; Sferrazza Papa GF; Vicenzi M; Santus P; Busatto P; Piffer F; Blasi F; Centanni S
Pulm Pharmacol Ther; 2012 Feb; 25(1):119-23. PubMed ID: 22245487
[TBL] [Abstract][Full Text] [Related]
18. HIV infection is associated with reduced pulmonary diffusing capacity.
Crothers K; McGinnis K; Kleerup E; Wongtrakool C; Hoo GS; Kim J; Sharafkhaneh A; Huang L; Luo Z; Thompson B; Diaz P; Kirk GD; Rom W; Detels R; Kingsley L; Morris A
J Acquir Immune Defic Syndr; 2013 Nov; 64(3):271-8. PubMed ID: 23979001
[TBL] [Abstract][Full Text] [Related]
19. Risk of COPD with obstruction in active smokers with normal spirometry and reduced diffusion capacity.
Harvey BG; Strulovici-Barel Y; Kaner RJ; Sanders A; Vincent TL; Mezey JG; Crystal RG
Eur Respir J; 2015 Dec; 46(6):1589-1597. PubMed ID: 26541521
[TBL] [Abstract][Full Text] [Related]
20. A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin.
Dimopoulou I; Galani H; Dafni U; Samakovii A; Roussos C; Dimopoulos MA
Cancer; 2002 Jan; 94(2):452-8. PubMed ID: 11900231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
